Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.
Journal: British journal of haematology
Published: December 22, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 14, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.
Journal: British journal of haematology
Published: April 19, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Journal: Blood advances
Published: April 15, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Journal: Blood advances
Published: April 15, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Journal: Blood advances
Published: April 15, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.
Journal: Blood advances
Published: March 28, 2025
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Journal: Lancet (London, England)
Published: March 26, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up.
Journal: Haematologica
Published: November 19, 2024
Last Updated: 09/26/2026